Codiak BioSciences, Inc.

General Information

We are a development-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases (cancer, neuromuscular disease and infectious diseases) with high unmet medical need. Exosomes are intercellular transfer mechanisms; they have emerged in recent years as a compelling potential drug delivery vehicle.

There have been no approved exosome-based therapeutics to date.

Our lead product candidates are being developed to treat solid tumors. We expect to enter clinical trials in the second half of 2020.



Industry: Pharmaceuticals
Employees: 101
Founded: 2015
Contact Information
Address 35 Cambridge Park Drive, Suite 500 Cambridge, MA 02140
Phone Number (617) 949-4100
Web Address
View Prospectus: Codiak BioSciences, Inc.
Financial Information
Market Cap $278.9mil
Revenues $0 mil (last 12 months)
Net Income $-80.7 mil (last 12 months)
IPO Profile
Symbol CDAK
Exchange NASDAQ
Shares (millions): 5.5
Price range $14.00 - $16.00
Est. $ Volume $82.5 mil
Manager / Joint Managers Goldman Sachs/ Evercore/ William Blair/ Wedbush Securities
CO-Managers -
Expected To Trade: 10/14/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change